Hydromorphone

bronchial asthma in unmonitored settings, severe COPD with CO₂ retention

Hydromorphone depresses respiratory drive via brainstem MOR activation. In patients with compromised baseline ventilation — severe asthma, COPD with hypercapnia — even therapeutic doses can precipitate respiratory failure. Contraindicated in unmonitored settings.

Hydromorphone can elevate intracranial pressure through CO₂ retention secondary to respiratory depression. Additionally, miosis and sedation obscure neurological monitoring. Class-level mu-opioid agonist contraindication.

Hydromorphone undergoes extensive first-pass hepatic metabolism. In severe hepatic impairment, oral bioavailability increases substantially and clearance decreases, necessitating dose reduction. The magnitude of dose adjustment is not precisely defined but conservative titration is recommended.

Hydromorphone-3-glucuronide (H3G) accumulates at ~4× normal levels in renal insufficiency. H3G is neuroexcitatory, producing allodynia, myoclonus, and seizures. Hydromorphone is often preferred over morphine in renal impairment (no active M6G equivalent), but dose reduction and neuroexcitatory monitoring are required. Consider opioid rotation if symptoms emerge.

Patients with documented hypersensitivity to hydromorphone or sulfite preservatives present in some injectable formulations should not receive hydromorphone. Cross-reactivity with other phenanthrene opioids (morphine, codeine) is possible.

Chronic hydromorphone use during pregnancy can cause neonatal opioid withdrawal syndrome (NAS). Acute use near delivery carries risk of neonatal respiratory depression. This is a class-level opioid effect; hydromorphone-specific teratogenicity data are limited.

Elderly patients demonstrate increased sensitivity to hydromorphone's respiratory and CNS depressant effects. Dose reduction is recommended. Chang et al. evaluated IV hydromorphone safety in elderly ED patients, providing the most robust safety data in this population.

Hydromorphone activates peripheral mu-opioid receptors in the GI tract, reducing peristalsis and increasing sphincter tone. In patients with mechanical obstruction or paralytic ileus, this further impairs motility and raises risk of bowel perforation.

Co-administration of hydromorphone with MAO inhibitors (or within 14 days of MAOI discontinuation) carries risk of severe, potentially fatal CNS depression and unpredictable autonomic reactions. This is a class-level opioid warning; hydromorphone-specific case data are lacking.

Co-administration of hydromorphone with other CNS depressants produces synergistic (not merely additive) respiratory depression. Benzodiazepine-opioid combinations are responsible for a significant proportion of opioid overdose fatalities. If concurrent use is clinically necessary, careful dose titration and monitoring are required.